Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus

被引：5

作者：

Fisher, Kurt W. ^{[1
]}

Lopez-Beltran, Antonio ^{[2
,3
]}

Montironi, Rodolfo ^{[4
]}

Cheng, Liang ^{[1
]}

机构：

[1] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[2] Fac Med, Dept Surg, Unit Anat Pathol, E-14004 Cordoba, Spain

[3] Champalimaud Clin Ctr, P-1400038 Lisbon, Portugal

[4] Polytech Univ Marche Reg, Sch Med, Pathol Anat, Ancona, Italy

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 19期

关键词：

BRAF; colorectal cancer; KRAS; microsatellite instability; molecular diagnostics; NRAS; personalized medicine; CIRCULATING TUMOR-CELLS; COST-EFFECTIVENESS ANALYSIS; GROWTH-FACTOR RECEPTOR; BRAF MUTATION ANALYSIS; ISLAND METHYLATOR PHENOTYPE; CETUXIMAB PLUS IRINOTECAN; MISMATCH REPAIR STATUS; MULTICENTER PHASE-II; KRAS CODON 61; MICROSATELLITE INSTABILITY;

D O I：

10.2217/fon.15.219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive molecular characterization has led to subclassification of colorectal adenocarcinoma based on molecular properties, such as microsatellite instability and high CpG island methylation. These emerging subclassifications are associate with varying frequencies of RAS, BRAF, APC and other genetic events and have the ability to redefine therapeutic regimens. In this review, we examine how molecular diagnostics are currently used while providing insight into emerging implications for molecular analysis for personalized therapy in colorectal cancer.

引用

页码：2711 / 2719

页数：9

共 77 条

[61]

Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21395, 10.3322/caac.21220]

[62] Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes [J].

Sinicrope, Frank A. ;

Shi, Qian ;

Smyrk, Thomas C. ;

Thibodeau, Stephen N. ;

Dienstmann, Rodrigo ;

Guinney, Justin ;

Bot, Brian M. ;

Tejpar, Sabine ;

Delorenzi, Mauro ;

Goldberg, Richard M. ;

Mahoney, Michelle ;

Sargent, Daniel J. ;

Alberts, Steven R. .

GASTROENTEROLOGY, 2015, 148 (01) :88-99

[63] Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy [J].

Sinicrope, Frank A. ;

Mahoney, Michelle R. ;

Smyrk, Thomas C. ;

Thibodeau, Stephen N. ;

Warren, Robert S. ;

Bertagnolli, Monica M. ;

Nelson, Garth D. ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Alberts, Steven R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3664-+

[64] DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy [J].

Sinicrope, Frank A. ;

Foster, Nathan R. ;

Thibodeau, Stephen N. ;

Marsoni, Silvia ;

Monges, Genevieve ;

Labianca, Roberto ;

Yothers, Greg ;

Allegra, Carmen ;

Moore, Malcolm J. ;

Gallinger, Steven ;

Sargent, Daniel J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (11) :863-875

[65] Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials [J].

Sorich, M. J. ;

Wiese, M. D. ;

Rowland, A. ;

Kichenadasse, G. ;

McKinnon, R. A. ;

Karapetis, C. S. .

ANNALS OF ONCOLOGY, 2015, 26 (01) :13-21

[66] Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer [J].

Spindler, Karen Lise Garm ;

Pallisgaard, Niels ;

Andersen, Rikke Fredslund ;

Brandslund, Ivan ;

Jakobsen, Anders .

PLOS ONE, 2015, 10 (04)

[67] Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma [J].

Spindler, Karen-Lise Garm ;

Pallisgaard, Niels ;

Andersen, Rikke Fredslund ;

Jakobsen, Anders .

INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (09) :2215-2222

[68] Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan [J].

Spindler, Karen-Lise Garm ;

Pallisgaard, Niels ;

Vogelius, Ivan ;

Jakobsen, Anders .

CLINICAL CANCER RESEARCH, 2012, 18 (04) :1177-1185

[69] Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients [J].

Suhaimi, Nur-Afidah Mohamed ;

Foong, Yu Miin ;

Lee, Daniel Yoke San ;

Phyo, Wai Min ;

Cima, Igor ;

Lee, Esther Xing Wei ;

Goh, Wei Lin ;

Lim, Wei-Yen ;

Chia, Kee Seng ;

Kong, Say Li ;

Gong, Min ;

Lim, Bing ;

Hillmer, Axel M. ;

Koh, Poh Koon ;

Ying, Jackie Y. ;

Tan, Min-Han .

MOLECULAR ONCOLOGY, 2015, 9 (04) :850-860

[70] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines [J].

Tahara, Makoto ;

Shirao, Kuniaki ;

Boku, Narikazu ;

Yamaguchi, Kensei ;

Komatsu, Yoshito ;

Inaba, Yoshitaka ;

Arai, Tatsuhiro ;

Mizunuma, Nobuyuki ;

Satoh, Taroh ;

Takiuchi, Hiroya ;

Nishina, Tomohiro ;

Sakata, Yuh .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) :762-769

← 1 2 3 4 5 6 7 8 →